Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + Busulfan + Melphalan Conditioning for ASCT in Multiple Myeloma
NCT01255527Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Oct 2010
- Primary completion
- Dec 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Yonsei University. Primary endpoint: Maximally Tolerated Dose at 28 days. Status: unknown.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01255527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01255527.